First Patient Dosed With CYAD-211, a Potential CAR T-cell Therapy

Home / Blog / First Patient Dosed With CYAD-211, a Potential CAR T-cell Therapy
First Patient Dosed With CYAD-211, a Potential CAR T-cell Therapy
January 23, 2021January 23, 2021
0

The first patient has been dosed in Celyad Oncology’s Phase 1 clinical trial evaluating CYAD-211, an investigational donor-derived CAR T-cell therapy for treating relapsed or refractory multiple myeloma. The IMMUNICY-1 trial (NCT04613557) intends to recruit 12 patients who received two or more prior lines of treatment, including an immunomodulatory agent and a proteasome inhibitor. Enrollment is ongoing in Belgium and the U.S. “Dosing the first patient with CYAD-211 marks another major milestone to systematically advance…

You must be logged in to read/download the full post.

The post First Patient Dosed With CYAD-211, a Potential CAR T-cell Therapy appeared first on BioNewsFeeds.